Health Press Release – Newsletter for January 26, 2011

His Highness Sheikh Mohammed bin Zayed Al Nahyan and the Bill & Melinda Gates Foundation Partner to Immunize Children

Together pledge $100 million to fight preventable diseases in Afghanistan and Pakistan

SEATTLE and ABU DHABI, United Arab Emirates, January 26, 2011 – His Highness Sheikh Mohammed bin Zayed Al Nahyan, the Crown Prince of Abu
Dhabi and Deputy Supreme Commander of the UAE Armed Forces, and Bill Gates,
Co-Chair of the Bill & Melinda Gates Foundation, … Read the original article on Gaea Times at : His Highness Sheikh Mohammed bin Zayed Al Nahyan and the Bill & Melinda Gates Foundation Partner to Immunize Children.

‘SOS Poison’ Smartphone app Saves Lives

ALMERE, The Netherlands, January 25, 2011 – What do you do when a child has eaten a buttercup? Should you induce
vomiting in a child when it has drunk bleach? Everyone with a smartphone can
immediately find answers to these types of questions by using the new SOS
Poison app. The app is available for iPhones as … Original source on Gaea Times at : 'SOS Poison' Smartphone app Saves Lives.

New Abbott Vitamin D Test Available for Use in the European Union

ABBOTT PARK, Illinois, January 25, 2011 – Abbott (NYSE: ABT) has announced CE marking (Conformite Europeenne) for
the ARCHITECT 25-OH Vitamin D assay, a new diagnostic test to measure levels
of vitamin D in blood using Abbott's ARCHITECT automated instrument system.

According to the International Osteoporosis Foundation, vitamin D
deficiency is a global health … Read more >>.

Practical Radiation Oncology Publishes First Issue

NEW YORK, January 25, 2011 – Elsevier, a world-leading publisher of scientific, technical, and medical
information products and services, is pleased to announce the publication of
the first issue of Practical Radiation Oncology (
www.elsevier.com/wps/find/journaldescription.cws_home/724612/description#description
)(PRO) on behalf of the American Society for Radiation Oncology (ASTRO).

(Due to the length of this URL, it may … Original article on : Practical Radiation Oncology Publishes First Issue.

Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer’s Disease

ASSERT Study Shows Increased Transport of Amyloid Beta 40
CALGARY, Alberta, January 25, 2011 – Resverlogix announced today that its lead drug RVX-208, a first in class
ApoA-I production drug, illustrated positive effects on an important
cognitive function and Alzheimer's Disease (AD) marker, plasma Amyloid beta
40 (Abeta40). This analysis was performed based on increasing evidence in the
literature … Original article on : Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's Disease.